New research from UC Davis Comprehensive Cancer Center has uncovered an evolutionary change that may explain why certain ...

Peter Moulding joined a clinical trial for the drug AMP945 not really knowing whether it would help him with deadly stage ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

The government is rolling out major reforms across its core sectors to fix deep-rooted problems and build a stronger economy.